<DOC>
	<DOCNO>NCT00223730</DOCNO>
	<brief_summary>Patients undergo bone marrow transplantation ( BMT ) peripheral blood stem cell transplant ( PBSCT ) frequently develop organ dysfunction , much may initiate damage liver cell line blood vessel . We , researcher Vanderbilt University , propose perform randomize , prospective , double-blind , placebo-controlled study 144 patient undergoing allogeneic marrow transplantation . The treatment aim support hepatic urea cycle function patient receive escalate dose chemotherapy/BMT . By hope prevent development hepatic venoocclusive disease ( HVOD ) acute lung injury ( ALI ) , two morbid complication BMT . Patients randomize receive oral citrulline , urea cycle amino acid intermediate , placebo begin condition therapy continue 21 day BMT . All patient follow 100 day study enrollment intensive data collection .</brief_summary>
	<brief_title>Chemotherapy Toxicity Reduction Via Urea Cycle Support</brief_title>
	<detailed_description />
	<criteria>We propose study 144 patient undergoing allogeneic bone marrow transplantation peripheral blood stem cell transplant 4 year period . Patients either sex race ethnic origin , old age great equal to13 , admit Myelosuppression Unit ( MSU ) Vanderbilt University Hospital VA Hospital undergo bone marrow transplantation recruit study . Patients exclude pregnant ( unlikely ) inform consent obtain . Because intrinsic toxicity treatment regimen , BMT usually offer patient severe underlying derangement organ function . Nevertheless , exclusion prevent entry patient study include advanced renal hepatic failure ( serum creatinine &gt; 6mg/dl , serum bilirubin &gt; 3.5 mg/dl ) , moribund patient , patient whose primary physician commit full support patient ( i.e . `` Do Not Resuscitate '' ) . Other exclusion include patient enrol another experimental ( interventional ) protocol aim reduce transplant related complication BMT , patient test positive HIV , previous BMT , patient actively bleed time initiation induction therapy . We exclude patient undergo new regimen cytotoxic chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Peripheral Blood Stem Cell Transplant</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Citrulline</keyword>
	<keyword>Urea Cycle</keyword>
	<keyword>Hepatic Injury</keyword>
	<keyword>Allogeneic PBSCT</keyword>
	<keyword>Matched-Unrelated PBSCT</keyword>
</DOC>